Fake news vaccine: study tests 'Prebunking' to shield young women from HIV drug myths
NCT ID NCT07518914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a short 'inoculation' message can help young women in South Africa resist misinformation about lenacapavir, a new twice-yearly injection for HIV prevention. 1,500 women aged 18-29 will be randomly assigned to receive either the inoculation message or unrelated health information, then exposed to false claims. Researchers will measure their intention to use lenacapavir and how believable they find the misinformation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this approach could help ensure that accurate information about lenacapavir reaches young women, supporting its uptake and HIV prevention efforts.
- What could go wrong
- This is a behavioral study, not a drug trial. It measures intentions, not actual HIV prevention. Results may not translate to real-world behavior or other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENACAPAVIR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Health Economics and Epidemiology Research Office, University of the Witwatersrand
RECRUITINGJohannesburg, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.